Dr. Peijun Zuo, BMSc, MMSc, PhD, is a distinguished researcher and lecturer in public health at Shantou University, with extensive expertise in preventive medicine, molecular biology, and biomedical engineering. He obtained his PhD in Biochemistry from the Chinese University of Hong Kong, a Master of Medical Science in Microbiology from the Chinese Center for Disease Control and Prevention, and a Bachelor of Medical Science in Preventive Medicine from Shanxi Medical University. Dr. Zuo’s professional trajectory spans roles as Research Assistant Professor at The University of Hong Kong, Research Associate at Duke University, and Visiting Fellow at the National Institutes of Health, with leadership positions in public health organizations and laboratory management. His research focuses on PCR micro/nanofluidic chip design, nanoparticle-based drug delivery, stem cell differentiation, vaccine development, pathogen detection, and antigen evolution, with numerous high-impact publications in translational medicine, immunology, and infectious diseases. Dr. Zuo has successfully secured competitive research grants, supervised graduate students, and contributed to advancing knowledge in SARS-CoV-2 antigen evolution, cancer molecular biology, and biomedical materials. He has been recognized with multiple scholarships and awards, including honors from the Chinese University of Hong Kong, German Cancer Research Foundation, Italian Ministry of University, and Hebei Provincial Health Bureau. He is an active member of the Chinese Association of Preventive Medicine and has made significant contributions to both scientific research and public health education, reflecting his commitment to innovation, interdisciplinary collaboration, and the translation of biomedical discoveries into practical applications.

Profile : Scopus

Featured Publications

Zuo, P., Zuo, L., Li, Z., Zhou, X., Yu, Y., Wu, Q., Niu, Y., Chang, Q., Rabie, A. B. M., Lam, P., & Li, L. (2025). Outbreak dates of virus could be predicted by their protein sequence. Journal of Translational Medicine, 23(1), 980.

Wu, Q., Ye, L., Wu, Y., Zhao, M., Lu, J., Yu, Y., Niu, Y., Zhang, L., & Zuo, P. (2025). Combining single-cell analysis and molecular docking techniques to construct a prognostic model for colon adenocarcinoma and uncovering inhibin subunit BB as a novel therapeutic target. Frontiers in Immunology, 15, 1524560.

Zuo, P., Zuo, L., Li, Z., & Li, L. (2024). Superantigens, antigen precision and their application in coronavirus. Diagnos Pathol Open, 9, 236.

Zuo, P., Zuo, L., Li, Z., & Li, L. (2024). Antigen evolution from D614, to D614G, to Delta, and to Omicron subtype of SARS-CoV-2. Human Biology, 94(2), 599–607.

Zuo, P., Zuo, L., Li, Z., & Li, L. (2024). Mutation and prediction of COVID-19. In Lecture Notes on Data Engineering and Communications Technologies (Vol. 207, pp. 422–433). Springer Nature Singapore Pte Ltd.